MedTrace Logo

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

NCT05233332 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2023-05-31

No results posted yet for this study

Summary

The study consists of the two parts, phase IIa and phase IIb.

Conditions

Interventions

DRUG

HL-085

12mg BID HL-085

DRUG

Vemurafenib

720mg BID Vemurafenib

Sponsors & Collaborators

  • Shanghai Kechow Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Hongqi Tian, Ph.D · Shanghai Kechow Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2024-01-20
Completion
2024-07-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233332 on ClinicalTrials.gov